March 2, 2020 / 6:30 AM / a month ago

BRIEF-Epigenomics: Centers For Medicare & Medicaid Services Open NCD Review Process For Epi proColon

March 2(Reuters) - EPIGENOMICS AG:

* SAID ON FRIDAY CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) OPENED NATIONAL COVERAGE DETERMINATION (NCD) REVIEW OF EPI PROCOLON, EPIGENOMICS’ BLOOD TEST FOR COLORECTAL CANCER SCREENING

* DECISION ON CMS’S REIMBURSEMENT OF EPI PROCOLON MUST BE MADE WITHIN MAXIMUM PERIOD OF NINE MONTHS

* POSITIVE CMS REIMBURSEMENT DECISION WOULD REPRESENT MAJOR BREAKTHROUGH FOR COMPANY IN COMMERCIALIZATION OF EPI PROCOLON IN US MARKET

Source text for Eikon:

Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below